Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (Lév.) Hutch Against IgA Nephropathy

References

• Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739–3746. doi:10.1681/ASN.2016010093
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33(4):661–669. doi:10.1093/ndt/gfx189
   PubMed Web of Science ®Google Scholar
• Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1
   PubMed Web of Science ®Google Scholar
• Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1–S276. doi:10.1016/j.kint.2021.05.021
   PubMedGoogle Scholar
• Wang XH, Lang R, Liang Y, Zeng Q, Chen N, Yu RH. Traditional Chinese medicine in treating IgA nephropathy: from basic science to clinical research. J Transl Int Med. 2021;9(3):161–167. doi:10.2478/jtim-2021-0021
   PubMed Web of Science ®Google Scholar
• Law SK, Simmons MP, Techen N, et al. Molecular analyses of the Chinese herb Leigongteng (Tripterygium wilfordii Hook.f.). Phytochemistry. 2011;72(1):21–26. doi:10.1016/j.phytochem.2010.10.015
   PubMed Web of Science ®Google Scholar
• Zhang X, Li N, Yao Y, et al. Identification of species in Tripterygium (Celastraceae) based on DNA barcoding. Biol Pharm Bull. 2016;39(11):1760–1766. doi:10.1248/bpb.b15-00956
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang F, Xiao X, et al. Tripterygium hypoglaucum (Lévl.) Hutch and its main bioactive components: recent advances in pharmacological activity, pharmacokinetics and potential toxicity. Front Pharmacol. 2021;12:715359. doi:10.3389/fphar.2021.715359
   PubMed Web of Science ®Google Scholar
• Tong X, Qiao Y, Yang Y, et al. Applications and mechanisms of Tripterygium wilfordii Hook. F. and its preparations in kidney diseases. Front Pharmacol. 2022;13:846746. doi:10.3389/fphar.2022.846746
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhong M, Long F, Yang R. Deciphering the active ingredients and molecular mechanisms of Tripterygium hypoglaucum (Levl.) Hutch against rheumatoid arthritis based on network pharmacology. Evid Based Complement Alternat Med. 2020;2020:2361865. doi:10.1155/2020/2361865
   PubMed Web of Science ®Google Scholar
• Li F, Han D, Wang B, et al. Topical treatment of colquhounia root relieves skin inflammation and itch in imiquimod-induced psoriasiform dermatitis in mice. Mediators Inflamm. 2022;2022:5782922. doi:10.1155/2022/5782922
   PubMed Web of Science ®Google Scholar
• Ma Z, Liu Y, Li C, Zhang Y, Lin N. Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation. Chin Med. 2022;17(1):2. doi:10.1186/s13020-021-00563-7
   PubMed Web of Science ®Google Scholar
• Zhu B, Wang Y, Jardine M, et al. Tripterygium preparations for the treatment of CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(3):515–530. doi:10.1053/j.ajkd.2013.02.374
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110–1111. doi:10.1038/nbt1007-1110
   PubMed Web of Science ®Google Scholar
• Wei TF, Zhao L, Huang P, et al. Qing-Yi decoction in the treatment of acute pancreatitis: an integrated approach based on chemical profile, network pharmacology, molecular docking and experimental evaluation. Front Pharmacol. 2021;12:590994. doi:10.3389/fphar.2021.590994
   PubMed Web of Science ®Google Scholar
• Su X, Kong L, Lei X, Hu L, Ye M, Zou H. Biological fingerprinting analysis of traditional Chinese medicines with targeting ADME/Tox property for screening of bioactive compounds by chromatographic and MS methods. Mini Rev Med Chem. 2007;7(1):87–98. doi:10.2174/138955707779317830
   PubMed Web of Science ®Google Scholar
• Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43(Databaseissue):D789–D798. doi:10.1093/nar/gku1205
   PubMedGoogle Scholar
• Fishilevich S, Zimmerman S, Kohn A, et al. Genic insights from integrated human proteomics in GeneCards. Database. 2016;2016:baw030. doi:10.1093/database/baw030
   PubMedGoogle Scholar
• Martino E, Chiarugi S, Margheriti F, Garau G. Mapping, structure and modulation of PPI. Front Chem. 2021;9:718405. doi:10.3389/fchem.2021.718405
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Zhao L, Lan Z, Peng L, et al. Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway. Cell Prolif. 2022;55(9):e13278. doi:10.1111/cpr.13278
   PubMed Web of Science ®Google Scholar
• Pace S, Zhang K, Jordan PM, et al. Anti-inflammatory celastrol promotes a switch from leukotriene biosynthesis to formation of specialized pro-resolving lipid mediators. Pharmacol Res. 2021;167:105556. doi:10.1016/j.phrs.2021.105556
   PubMed Web of Science ®Google Scholar
• Xia M, Liu D, Tang X, et al. Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway. Int Immunopharmacol. 2020;80:106125. doi:10.1016/j.intimp.2019.106125
   PubMed Web of Science ®Google Scholar
• Saikia S, Bordoloi M. Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets. 2019;20(5):501–521. doi:10.2174/1389450119666181022153016
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol. 2015;10(7):1170–1178. doi:10.2215/CJN.11261114
   PubMed Web of Science ®Google Scholar
• Huang X, Xu G. An update on targeted treatment of IgA nephropathy: an autoimmune perspective. Front Pharmacol. 2021;12:715253. doi:10.3389/fphar.2021.715253
   PubMed Web of Science ®Google Scholar
• Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686. doi:10.2215/CJN.07420716
   PubMed Web of Science ®Google Scholar
• Guo Y, Guo N, Wang J, Wang R, Tang L. Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria. Ren Fail. 2021;43(1):729–736. doi:10.1080/0886022X.2021.1918555
   PubMed Web of Science ®Google Scholar
• Zhang H, Li X, Xu H, Ran F, Zhao G. Effect and safety evaluation of tacrolimus and tripterygium glycosides combined therapy in treatment of Henoch-Schönlein purpura nephritis. Int J Urol. 2021;28(11):1157–1163. doi:10.1111/iju.14665
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen Y, Yang MJ, et al. Celastrol attenuates renal injury in diabetic rats via MAPK/NF-κB pathway. Phytother Res. 2019;33(4):1191–1198. doi:10.1002/ptr.6314
   PubMed Web of Science ®Google Scholar
• Ma ZJ, Zhang XN, Li L, et al. Tripterygium glycosides tablet ameliorates renal tubulointerstitial fibrosis via the toll-like receptor 4/nuclear factor kappa B signaling pathway in high-fat diet fed and streptozotocin-induced diabetic rats. J Diabetes Res. 2015;2015:390428. doi:10.1155/2015/390428
   PubMed Web of Science ®Google Scholar
• He L, Peng X, Liu G, et al. Anti-inflammatory effects of triptolide on IgA nephropathy in rats. Immunopharmacol Immunotoxicol. 2015;37(5):421–427. doi:10.3109/08923973.2015.1080265
   PubMed Web of Science ®Google Scholar
• Gao Q, Shen W, Qin W, et al. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010;25(11):3539–3547. doi:10.1093/ndt/gfq245
   PubMed Web of Science ®Google Scholar
• Tamouza H, Chemouny JM, Raskova Kafkova L, et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int. 2012;82(12):1284–1296. doi:10.1038/ki.2012.192
   PubMed Web of Science ®Google Scholar
• Chen W, Yuan H, Cao W, et al. Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. Theranostics. 2019;9(14):3980–3991. doi:10.7150/thno.32352
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang D, Wang F, et al. Endogenous miR-204 protects the kidney against chronic injury in hypertension and diabetes. J Am Soc Nephrol. 2020;31(7):1539–1554. doi:10.1681/ASN.2019101100
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Tsoi LC, Hu Y, et al. Exome chip analyses and genetic risk for IgA nephropathy among Han Chinese. Clin J Am Soc Nephrol. 2021;16(2):213–224. doi:10.2215/CJN.06910520
   PubMed Web of Science ®Google Scholar
• Tang C, Ma Z, Zhu J, et al. P53 in kidney injury and repair: mechanism and therapeutic potentials. Pharmacol Ther. 2019;195:5–12. doi:10.1016/j.pharmthera.2018.10.013
   PubMed Web of Science ®Google Scholar
• Yakulov TA, Todkar AP, Slanchev K, et al. CXCL12 and MYC control energy metabolism to support adaptive responses after kidney injury. Nat Commun. 2018;9(1):3660. doi:10.1038/s41467-018-06094-4
   PubMedGoogle Scholar
• Xia M, Liu D, Liu H, et al. Based on network pharmacology tools to investigate the mechanism of Tripterygium wilfordii against IgA nephropathy. Front Med. 2021;8:794962. doi:10.3389/fmed.2021.794962
   Web of Science ®Google Scholar
• Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007;130(5):769–774. doi:10.1016/j.cell.2007.08.021
   PubMed Web of Science ®Google Scholar
• Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. 2015;161(5):999–1011. doi:10.1016/j.cell.2015.05.011
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao Y, Luo W, et al. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics. 2020;10(22):10290–10308. doi:10.7150/thno.46728
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang J, Wang Y, et al. Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment. Nano Res. 2022;15(4):3556–3568. doi:10.1007/s12274-021-3894-x
   PubMed Web of Science ®Google Scholar
• Sun Z, Li Y, Qian Y, et al. Celastrol attenuates ox-LDL-induced mesangial cell proliferation via suppressing NLRP3 inflammasome activation. Cell Death Discov. 2019;5:114. doi:10.1038/s41420-019-0196-0
   PubMed Web of Science ®Google Scholar
• Guo L, Luo S, Du Z, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun. 2017;8(1):878. doi:10.1038/s41467-017-00834-8
   PubMed Web of Science ®Google Scholar
• Zhan X, Yan C, Chen Y, et al. Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway. Mol Immunol. 2018;104:61–68. doi:10.1016/j.molimm.2018.10.021
   PubMed Web of Science ®Google Scholar
• Xiang G, Shi K, Wang J. Celastrol alleviates murine lupus nephritis via inducting CD4+Foxp3+ regulatory T cells. Folia Histochem Cytobiol. 2022;60(3):237–246. doi:10.5603/FHC.a2022.0020
   PubMed Web of Science ®Google Scholar
• Worby CA, Dixon JE. PTEN. Annu Rev Biochem. 2014;83:641–669. doi:10.1146/annurev-biochem-082411-113907
   PubMed Web of Science ®Google Scholar
• Chen JK, Nagai K, Chen J, et al. Phosphatidylinositol 3-kinase signaling determines kidney size. J Clin Invest. 2015;125(6):2429–2444. doi:10.1172/JCI78945
   PubMed Web of Science ®Google Scholar
• Li Y, Xia M, Peng L, et al. Downregulation of miR‑214-3p attenuates mesangial hypercellularity by targeting PTEN‑mediated JNK/c-Jun signaling in IgA nephropathy. Int J Biol Sci. 2021;17(13):3343–3355. doi:10.7150/ijbs.61274
   PubMed Web of Science ®Google Scholar